Program
mitapivat
Also written as “Mitapivat”, “AG-348” and “Mitapivat tablet”.
Its studies are mostly in beta-Thalassemia · Anemia, Hemolytic · Anemia, Sickle Cell · Anemia · Thalassemia, led by Agios Pharmaceuticals.
Furthest: phase 4, since Mar 9, 202324 company-led studies, 10 open or runningNext primary completion: Mar 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 2410 open or running | phase 4since Mar 9, 2023 | Apr 2, 2014 | Mar 2029phase 3 · NCT07517133 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Apr 2, 2014.
- Sep 10, 2018Phase 2 study in ThalassemiaNCT03692052 · 20 enrolled · United States, Canada, United Kingdom
- Feb 22, 2019Phase 3 study in Pyruvate Kinase Deficiency of Red CellsNCT03853798 · 90 enrolled · United States, Brazil, Canada and more
- Jul 13, 2020Phase 1 study in Healthy VolunteersNCT04472832 · 32 enrolled · United States
- Sep 22, 2020Phase 1 study in Healthy VolunteersNCT04565678 · 32 enrolled · United States
- Jan 4, 2021Phase 1 study in Healthy VolunteersNCT04696393 · 26 enrolled · United States
- Feb 18, 20212 phase 3 studiesNCT04770779, NCT04770753
- Jul 29, 2021Phase 3 study in Anemia, Sickle CellNCT05031780 · 286 enrolled · United States, Belgium, Brazil and more
- Nov 22, 20212 phase 3 studies in AnemiaNCT05175105, NCT05144256
- Nov 3, 2022Phase 1 study in Moderate Hepatic ImpairmentNCT05610657 · 20 enrolled · United States
- Mar 9, 2023Phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993 · 55 planned · Belgium, Brazil, Canada and more
- Feb 23, 2024Phase 2 study in Anemia, Sickle CellNCT06286046
- Oct 17, 2024Phase 1 study in Healthy ParticipantsNCT06648824 · 20 enrolled · United States
- Mar 26, 20262 phase 3 studiesNCT07517133, NCT07506863
- Jun 15, 2026Phase 3 study in Anemia, Sickle CellNCT07656415 · 159 planned · United States
Ahead
- Mar 2029Primary completion: phase 3 study in Non-Transfusion-dependent Alpha-ThalassemiaNCT07517133
- Jun 2029Primary completion: phase 3 study in Transfusion-dependent Alpha-ThalassemiaNCT07506863
- Aug 2029Primary completion: phase 3 study in Anemia, Sickle CellNCT07656415
- Aug 2029Primary completion: phase 4 study in Pyruvate Kinase Deficiency of Red CellsNCT05777993
TargetBeta
PKLR →read by rule
“Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator; Pyruvate kinase isozymes R/L activator”ChEMBL 37, by rule
Other programs on PKLR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etavopivat | Novo Nordisk | phase 3 | 12 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656415Anemia, Sickle Cell · United States | 3 | Recruiting | Aug 2029 | 159 |
| NCT07517133Non-Transfusion-dependent Alpha-Thalassemia · United States | 3 | Recruiting | Mar 2029 | 45 |
| NCT07506863Transfusion-dependent Alpha-Thalassemia · United States | 3 | Recruiting | Jun 2029 | 54 |
| NCT06648824Healthy Participants · United States | 1 | Completed | Dec 3, 2024 | 20 |
| NCT06286046Anemia, Sickle Cell | 2 | Withdrawn | May 2027 | 0 |
| NCT05777993Pyruvate Kinase Deficiency of Red Cells · Belgium, Brazil, Canada and more | 4 | By invitation | Aug 2029 | 55 |
| NCT05610657Moderate Hepatic Impairment · United States | 1 | Completed | Jul 21, 2023 | 20 |
| NCT05175105Anemia · United States, Canada, France and more | 3 | Active, not recruiting | Dec 13, 2024 | 30 |
| NCT05144256Anemia · United States, Canada, Czechia and more | 3 | Active, not recruiting | May 3, 2024 | 49 |
| NCT05031780Anemia, Sickle Cell · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Oct 30, 2025 | 286 |
| NCT04770779Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Apr 11, 2024 | 258 |
| NCT04770753Non-Transfusion-dependent Alpha-Thalassemia · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Nov 13, 2023 | 194 |
| NCT04696393Healthy Volunteers · United States | 1 | Completed | Mar 19, 2021 | 26 |
| NCT04565678Healthy Volunteers · United States | 1 | Completed | Dec 3, 2020 | 32 |
| NCT04472832Healthy Volunteers · United States | 1 | Completed | Nov 23, 2020 | 32 |
| NCT03853798Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more | 3 | Completed | Jul 3, 2024 | 90 |
| NCT03692052Thalassemia · United States, Canada, United Kingdom | 2 | Active, not recruiting | Aug 20, 2020 | 20 |
| NCT03703505Healthy Volunteers · United States | 1 | Completed | Jun 1, 2018 | 8 |
| NCT03548220Pyruvate Kinase Deficiency of Red Cells · United States, Brazil, Canada and more | 3 | Completed | Oct 9, 2020 | 80 |
| NCT03559699Pyruvate Kinase Deficiency of Red Cells · United States, Canada, Denmark and more | 3 | Completed | Nov 12, 2020 | 27 |
| NCT03250598Healthy · United States | 1 | Completed | Oct 2, 2017 | 60 |
| NCT02476916Pyruvate Kinase Deficiency of Red Cells · United States, Canada, France and more | 2 | Completed | May 8, 2017 | 52 |
| NCT02149966Healthy Volunteer · United States | 1 | Completed | Nov 2014 | 48 |
| NCT02108106Healthy Volunteer · United States | 1 | Completed | Aug 2014 | 48 |
How it is read
Names in the registry
- “Mitapivat”, 13 entries
- “AG-348”, 10 entries
- “Mitapivat tablet”, 1 entry
- “Mitapivat 100 mg”, 1 entry
- “Mitapivat 300 mg”, 1 entry
Conditions, from the studies’ own filings
- beta-Thalassemia, 4 studies
- Anemia, Hemolytic, 4 studies
- Anemia, Sickle Cell, 3 studies
- Anemia, 2 studies
- Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.